¤³¤Î¥Ú¡¼¥¸¡ÊKAMAGRA-100Âè°ì¼¡»ÈÍÑ ³º×ãÖ÷µÉ¡©¡ËÆâ¤Î¥¹¥­¥Ã¥×¥á¥Ë¥å¡¼
  1. ¥µ¥¤¥È¤Î¥á¥¤¥ó¥á¥Ë¥å¡¼¤Ø°Üư
  2. ¥µ¥¤¥È¤Î¥æ¡¼¥¶¥á¥Ë¥å¡¼¤Ø°Üư
  3. ¤³¤Î¥Ú¡¼¥¸¡ÊKAMAGRA-100Âè°ì¼¡»ÈÍÑ ³º×ãÖ÷µÉ¡©¡Ë¤Î¥á¥¤¥ó¥³¥ó¥Æ¥ó¥Ä¤Ø°Üư

°Ê²¼¡¢¤³¤Î¥Ú¡¼¥¸(KAMAGRA-100Âè°ì¼¡»ÈÍÑ ³º×ãÖ÷µÉ¡©)¤Î¥á¥¤¥ó¥³¥ó¥Æ¥ó¥Ä¤Ç¤¹¡£

¥³¥ß¥å¥Ë¥Æ¥£¡§
KAMAGRA-100Âè°ì¼¡»ÈÍÑ ³º×ãÖ÷µÉ¡©¡Ê¤´¶á½ê¤Î³¹¥Í¥¿¡Ë

KAMAGRA-100Âè°ì¼¡»ÈÍÑ ³º×ãÖ÷µÉ¡©
¥²¥¹¥È Õôµö¿ÃËÀ­¼©¸À¡¤Âè°ì¼¡ÉþÍÑ KAMAGRA-100 ¿å²ÌÌ£¸ý´ÞÊÒ ±ý±ý´û´üÂÔËô¶ÛÄ¥¡£Çç´¾°õÅÙÀ½Â¤Åª ÔãÍÛ黡ÊSildenafil 100mg¡Ë °Ê¶ ¸ý´Þ¨²½¡¢²÷®µÛÚÀ¡¢Â¿¼ï¿å²Ì¸ýÌ£ ÏÂ ÊØ±÷Ú¸Öè ŪÆÃÀ­¡¤ºß¿·¼êÃËÀ­ÃæÈó¾ï¼õÝÄ·Þ¡£Àµ³ÎŪ»ÈÍÑÊýË¡ÉԶϱƶÁé»ÚᤴÔïð·¸Åþ°ÂÁ´çÐÉûºîÍѹµÀ©¡£ËÜʸÕò·ë¹ç Õó²È·úµÄ¡¢Î×¾²ÚËÚ¡°ÊµÚ»ÈÍѼԲóñ¿¡¤Äó¶¡Âè°ì¼¡»ÈÍÑ KAMAGRA-100 Ū´°À°¿·¼ê¶µÕÜ¡£

3330.jpg

°ì¡¢Î»²ò KAMAGRA-100 ¸ý´ÞÊÒŪé»ÍýÆÃÀ­
KAMAGRA-100 ¿å²ÌÌ£¸ý´ÞÊÒ À§°ì¼ï PDE5 ÍÞÀ©Ñý¡¤³èÀ­À®Ê¬°Ù À¾ÃÏÆáÈó¡ÊSildenafil¡Ë¡£Â¶¼çÍ׺îÍѵ¡À©Ç¡²¼¡§

ÍÞÀ© PDE5 酶³èÀ­

PDE5 À§±¢è³³¤ÌÊñó內ʬ²ò cGMP Ūïð¸°酶¡£

À¾ÃÏÆáÈó²ÄÍÞÀ© PDE5¡¤»È cGMP ¿åÊ¿¾£¹â¡¤Â¥¿ÊÊ¿³êȩаĥ¡¤ùá²Ã·ìή¡¤Ã£ÅþËÖµ¯Úò̡£

¸ý´ÞµÛÚÀ²÷

é»ÊªÆ©²á¸ý¹ÐóÖËìľÀÜ¿ÊÆþ·ì±Õ¡¤ÈòÌÈÉôʬ¼óÅÏÂå¼Õ¡ÊFirst-pass metabolism¡Ë¡¤ÈæÑ£Åý¸ýÉþ¾ûµ¯Úù¹²÷¡£

Î×¾²»îñäðý¼¨¸ý´ÞÊÒµ¯ÚÃÊ¿¶Ñ»þ´Ö Ìó 15–30 ʬ¾â¡ÊÐÔ¸»¡§International Journal of Impotence Research, 2018¡Ë¡£

é»Úûýåô»þ´Ö

KAMAGRA-100 Ūé»ÚòĻýåô 4–6 ¾®»þ¡¤Éôʬ»ÈÍѼԲÄã 8 ¾®»þ¡¤çÐÀ­»É·ãƱ»þºîÍÑ¡£

Ç纳é»ÍýÃμ±Õô Âè°ì¼¡»ÈÍÑ KAMAGRA-100 Ū¿·¼ê Èó¾ï½ÅÍס¤²Ä幫½õÍý²ò°Ù½ºÖ÷ ¶õÊ¢ÉþÍѵ¯Úù¹²÷¡¤°ÊµÚ°Ù²¿À­»É·ãɬ¿Ü¸ºßºÍǽãÅþËÖµ¯Úò̡£



Æó¡¢¼ó¼¡»ÈÍÑ KAMAGRA-100 Á°Åª½àÈ÷
Âè°ì¼¡»ÈÍÑ KAMAGRA-100 Á°¡¤·úµÄÃí°Õ°Ê²¼»ö¹à¡§

»ðëÎîлÕ

³Îǧ¼«¿ÈÝóÍ­ Óî½Å¿´·ì´É¼ÀÉ¡¢Äã·ìÔÚ°¿¹â·ìÔÚ¡¤°¿ÀµºßÉþÍÑ ¾Ë»ÀóÅÎàé»Êª¡£

¸¦µæðý¼¨¡¤¿´·ì´É´µ¼Ôºß̤»ðëÎîлÕŪ¾ð¶·²¼»ÈÍÑ PDE5 ÍÞÀ©Ñý¡¤²Äǽùá²Ã¿´È©åþ·ìÉ÷ðª¡ÊÐÔ¸»¡§American Heart Association, 2020¡Ë¡£

ÁªÚ¤¶õÊ¢°¿íË¿©狀ÂÖ

¹â»é»ÁÐò±äî¯é»ÊªµÛÚÀ 60–120 ʬ¾â¡¤¹ßÄã·ìé»Ç»ÅÙ 20–30%¡ÊÐÔ¸»¡§Journal of Sexual Medicine, 2016¡Ë¡£

¶õÊ¢ÉþÍÑǽÄó¹â·ìÃæÀ¾ÃÏÆáÈóÇ»ÅÙ¡¤Äó¾£ËÖµ¯¹ÅÅÙÏ»ýåô»þ´Ö¡£

½àÈ÷¾¯ÎÌ¿å

ê­Á³¸ý´ÞÊÒ²ÄľÀܵÛÚÀ¡¤Ã¢¸ý´¥»þ¾¯ÎÌ¿åÍ­½õ±÷é»ÊÒÍϲò¡£

ÊÝ»ýаŬ¡¢Êüò¢Åª´Ä¶­

¿´Íý狀ÂÖçÐÀ­»É·ãÐò±Æ¶Áé»Úá¤Êüò¢¿´¾ð²ÄÄó¹â KAMAGRA-100 ŪͭÚÃÀ­¡£

3333.png

»°¡¢¼ó¼¡ÉþÍÑ KAMAGRA-100 Ū步ñå
µ¯»ÏÑýÎÌ

·úµÄ¿·¼ê×Ï 50mg ³«»Ï¡Ê65 歲°Ê¾åÃËÀ­²Ä×Ï 25mg ³«»Ï¡Ë¡£

¼ãÚòÌÉÔ­¡¤²ÄÄ´À°»ê 100mg¡¤Ã¢每ÆüÉÔ²ÄͲá 100mg¡£

ÉþÍÑÊýË¡

Õò¸ý´ÞÊÒÊüÆþ¸ýÃæ¼«Á³Íϲò¡¤ÈòÌÈÒòÓð°¿Ä¾ÀÜ吞²¼¡£

µ¯ÚÃÊ¿¶Ñ 15–30 ʬ¾â¡¤é»ÚòĻýåô 4–6 ¾®»þ¡¤Éôʬ»ÈÍѼԲÄã 8 ¾®»þ¡£

À­»É·ãɬ¿Ü¸ºß

PDE5 ÍÞÀ©Ñý¶ÏºßÀ­»É·ã²¼â¤´øºîÍÑ¡¤ÓŽãÉþÍÑ̵ˡ¼«Æ°ËÖµ¯¡£

ë·»¡ÉûºîÍÑ

¾ï¸«íËÈùÉûºîÍÑÊñ³ç¡§Æ¬Úô¡¢çÀ¹È¡¢É¡ºÉ¡¢íËÈùƬÄË¡£

¼ã½Ð¸½¶»Ìå¡¢·àÎõƬÄ˰¿»ëÎÏ°Û¾ï¡¤ØæÎ©Â¨Ääé»Ê½¢îС£

ÈþÔ¢ FDA ·úµÄ¡¤½Ð¸½Óî½ÅÉûºîÍÑ»þ¡¤ØæÎ©Â¨ÙûÂǵ޵ßÅÅÏð¿Á°±ýµÞ¿Ç¡ÊÐÔ¸»¡§FDA Drug Safety Communication, 2019¡Ë¡£

33.png

»Í¡¢¶õÊ¢çÐÈÓ¸åÉþÍÑ KAMAGRA-100 Ūº¹°Û
¶õÊ¢ÉþÍÑ

µ¯ÚúDz÷¡¤·ìÃæÀ¾ÃÏÆáÈóÇ»ÅÙãÊö»þ´ÖºÇû¡£

Î×¾²ÚËÚ¡ðý¼¨¡¤¶õÊ¢ÉþÍѲĻÈÊ¿¶Ñµ¯Úûþ´Ö½ÌûÌó 20 ʬ¾â¡ÊÐÔ¸»¡§International Journal of Clinical Pharmacology, 2017¡Ë¡£

íË¿©¸åÉþÍÑ

°ßÉÒ´¶¼Ô²ÄÁªÚ¤¡¤Ã¢µ¯ÚÃãÄËý¡¤·ìÃæÇ»ÅÙάÄã¡£

¹â»é»Á¸åÉþÍÑ

µ¯Úñäî¯ 60–120 ʬ¾â¡¤é»ÚùßÄã¡£

Õó²È·úµÄ¿·¼êºÇ¹¥ÁªÚ¤ ¶õÊ¢°¿íË¿©¸å 1–2 ¾®»þ ÉþÍÑ¡¤°Ê³ÍÆÀºÇ²Â KAMAGRA-100 µ¯ÚÃÚò̡£

23232323.png

¸Þ¡¢KAMAGRA-100°ÂÁ´»ÈÍÑçÐÃí°Õ»ö¹à
ÈòÌÈçо˻ÀóÅÎàé»ÊªÆ±»þ»ÈÍÑ

²ÄǽƳÃ×·ìÔڵ޹ߡ¤ùá²Ã¿´·ì´ÉÉ÷𪡣

ÈòÌȹâ»é»ÁçвáÎ̼òÀº

²Ä¹ßÄã·ìÃæÇ»ÅÙ¡¤±Æ¶ÁËÖµ¯¹ÅÅÙ¡£

½å¼éÑýÎ̵¬ÈÏ

每ÆüÉÔ²ÄͲá 100mg¡¤ÈòÌÈùá²ÃÉûºîÍÑÉ÷𪡣

α°Õ¸Ä¿Íñó¼ÁÈ¿Øæ

¼ã½Ð¸½Æ¬Úô¡¢»ëÎϰ۾¶»ÌåÅù¾É狀¡¤Î©Â¨Ääé»Ê½¢îС£

Ï»¡¢·ëÏÀ¡§¿·¼ê»ÈÍÑ KAMAGRA-100 Ū黃¶âºöά
Âè°ì¼¡»ÈÍÑ KAMAGRA-100 ¿å²ÌÌ£¸ý´ÞÊÒ ÅªÃËÀ­¡¤²Ä½å½Û°Ê²¼ºöά¡§

Àè»ðëÎîлճÎǧ°ÂÁ´¡£

ÁªÚ¤ ¶õÊ¢°¿íË¿©¸å 1–2 ¾®»þ ÉþÍÑ¡£

µ¯»ÏÑýÎÌ 50mg¡¤É¬Í×»þÄ´À°»ê 100mg¡£

¸ý´ÞÊÒÊüÆþ¸ýÃæ¼«Á³Íϲò¡¤ÅùÂÔ 15–30 ʬ¾â µ¯Úá£

À­»É·ãɬ¿Ü¸ºß¡¤ÊÂë·»¡ÉûºîÍÑ¡£

¾¸°®°Ê¾åÊýË¡¡¤¿·¼êÌéǽ °ÂÁ´¡¢Í­ÚÃÃÏ»ÈÍÑ KAMAGRA-100¡¤Äó¾£ËÖµ¯¹ÅÅÙçлýµ×ÅÙ¡¤½Å½¦À­À¸³è¿®¿´¡£

Áêïð產ÉÊ¿äÁ¦¡§°õÅÙ½ã¿Ê¸ýÀµÉÊÉ¬ÍøÒ¦Priligy(POXET-60) Climax°õÅÙ¿ÀÌý ÈþÔ¢黃¶â°ÎÓ§Viagra °õÅÙÒÖÚÃÜÛ°ÒÔã¡ÊLevifil¡Ë ÈþÔ¢¡ÚMMC¡ÛMAXMAN  ±ÕÂÖ²ÌÅà°Ò¼©¹ÝMALEGRA üî¿åµ´ Extra Super FilanaÂè»ÍÂåAvanafil͵é°Ò¼©¹ÝÒÖÚà ¹¹Â¿產Éʾܾð¿ÊÆþ¹¯ÜÛé»¶Éwww.kl19.tw 24¾®»þµÒÉþline:kl198888

±ä¿­閱즡§KAMAGRA-100 Àµ³Î»ÈÍÑÊýË¡çÐÑýÎÌ»ØÆî
 

¤³¤Î¥¹¥ì¥Ã¥É¡ÊKAMAGRA-100Âè°ì¼¡»ÈÍÑ ³º×ãÖ÷µÉ¡©¡Ë¤ËÅê¹Æ

[Åê¹Æµ­»ö¤Îºï½ü¥¬¥¤¥É¥é¥¤¥ó¤Ï¤³¤Á¤é¡ÊPDF¡Ë]

Âê̾
¥²¥¹¥È̾
Åê¹ÆËÜʸ
²èÁü¤ÎÅê¹Æ


°Ê²¼¡¢¤³¤Î¥µ¥¤¥È(¤ß¤ó¤Ê¤ÎÁ¥¶¶)¤Î¥æ¡¼¥¶ÍÑ¥á¥Ë¥å¡¼¤È¡¢ÅÐÏ¿¤µ¤ì¤¿Á¥¶¶ Çð »ÔÀî ½¬»ÖÌî ȬÀéÂå ¤Î´ë¶È¤ªÅ¹¾ðÊó¤Î¥«¥Æ¥´¥ê°ìÍ÷¤Ç¤¹¡£
¤³¤Î¥Ú¡¼¥¸¤ÎÀèÆ¬¤ØÌá¤ë

¤³¤ó¤Ð¤ó¤Ï¡ª
¥²¥¹¥È¤µ¤ó

¥²¥¹¥È¤µ¤ó